(Bloomberg) -- Sosei Group Corp. has lost over half of its market value in just three days on concern about its outlook after Pfizer Inc. said Monday it will discontinue the partnered development of a diabetes and obesity drug.Most Read from BloombergSwitzerland Blocks Sale of Leopard 1 Tanks Bound for UkrainePutin Claims He’s Back in Control. Russia’s Elite Isn’t SureQatar Group Now Confident of Winning Manchester United RaceSweden Police Give Permit to Koran Burning Near Stockholm MosqueUBS Pr